Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...

AbbVie ABBV announced that the European Commission (“EC”) has granted marketing authorization to Elahere (mirvetuximab ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...

Ask yourself how the genetic test results may affect your life. If the results come back positive, will you take steps to ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...

Each cell in our body experiences up to tens of thousands of DNA-damaging events per day, primarily from routine cellular ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...

AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...

Oncologists caution that at-home genetic tests taken up by millions of Americans looking to gauge their cancer risk are not ...

Ellie Wilcock, 25, from Peterborough, admitted she 'never in a million years' expected to be diagnosed with bowel cancer at ...